{
    "organizations": [],
    "uuid": "41a7c4ac944a3285402b6dc24fb0bb0636f78e13",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/buzz-axovant-sciences-slumps-as-key-drug/buzz-axovant-sciences-slumps-as-key-drug-program-scrapped-idUSL4N1P33M1",
    "ord_in_thread": 0,
    "title": "BUZZ-Axovant Sciences: Slumps as key drug program scrapped",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "** Drug developer’s shares plunge 47.1 pct to $2.84 premarket - stock set to open at record low\n** Biggest pct loser among all U.S.-listed stocks premarket\n** Says to discontinue its intepirdine program after the lead experimental treatment failed in a mid-stage study on patients suffering from a type of dementia\n** Neither of the two doses of intepirdine given to patients with dementia with Lewy bodies resulted in improving their motor function, compared with patients given a placebo, Axovant said\n** In Sept, company said it would stop testing its lead drug in Alzheimer’s after it failed to meet the main goals of a late-stage trial\n** Pfizer is abandoning research to find new drugs aimed at treating Alzheimer’s and Parkinson’s disease, the U.S. pharmaceutical company announced on Saturday\n** Up to Friday’s close, AXON stock had fallen 77.9 percent since it announced the failed trial in Sept (Reporting by Akankshita Mukhopadhyay in Bengaluru)\n ",
    "published": "2018-01-08T20:55:00.000+02:00",
    "crawled": "2018-01-09T17:01:27.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "drug",
        "developer",
        "share",
        "plunge",
        "pct",
        "premarket",
        "stock",
        "set",
        "open",
        "record",
        "low",
        "biggest",
        "pct",
        "loser",
        "among",
        "stock",
        "premarket",
        "say",
        "discontinue",
        "intepirdine",
        "program",
        "lead",
        "experimental",
        "treatment",
        "failed",
        "study",
        "patient",
        "suffering",
        "type",
        "dementia",
        "neither",
        "two",
        "dos",
        "intepirdine",
        "given",
        "patient",
        "dementia",
        "lewy",
        "body",
        "resulted",
        "improving",
        "motor",
        "function",
        "compared",
        "patient",
        "given",
        "placebo",
        "axovant",
        "said",
        "sept",
        "company",
        "said",
        "would",
        "stop",
        "testing",
        "lead",
        "drug",
        "alzheimer",
        "failed",
        "meet",
        "main",
        "goal",
        "trial",
        "pfizer",
        "abandoning",
        "research",
        "find",
        "new",
        "drug",
        "aimed",
        "treating",
        "alzheimer",
        "parkinson",
        "disease",
        "pharmaceutical",
        "company",
        "announced",
        "saturday",
        "friday",
        "close",
        "axon",
        "stock",
        "fallen",
        "percent",
        "since",
        "announced",
        "failed",
        "trial",
        "sept",
        "reporting",
        "akankshita",
        "mukhopadhyay",
        "bengaluru"
    ]
}